Clinical trials: Acute Migraine
- Condition Acute Migraine
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents.
- Trial name
- NCT00210483
- Testing
- almotriptan malate
- Volunteers
- 866 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years. Part 1: Approximately 20 weeks (includes screening and double-blind treatment).
- Trial name
- NCT03275922
- Testing
- ZNS
- Where
- 47 sites in United States
- Volunteers
- 374 people
- Sponsor
- Impax Laboratories, LLC
Migraine, Acute Treatment of Migraine
Nerivio Efficacy by Time of Treatment Onset
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine.
- Trial name
- NCT06976723
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 55,261 people
- Sponsor
- Theranica
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Migraine
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged…
- Trial name
- NCT00617695
- Testing
- Zolmitriptan
- Volunteers
- 247 people
- Sponsor
- Impax Laboratories, LLC
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine Headache
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better.
- Trial name
- TEENZ (NCT01211145)
- Testing
- Zolmitriptan
- Where
- 74 sites in United States, Estonia and 6 more
- Volunteers
- 1,653 people
- Sponsor
- AstraZeneca
Acute Migraine With or Without Aura
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
- Trial name
- NCT03338920
- Testing
- sumatriptan nasal powder
- Where
- 40 sites in United States
- Volunteers
- 159 people
- Sponsor
- Currax Pharmaceuticals
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine, Acute Treatment of Migraine
Nerivio Long-term Usage in Patients With Migraine
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
- Trial name
- NCT06738056
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Theranica
Migraine in Adolescence
Real-world Data Analysis of REN Treatment in Adolescence With Migraine
This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine.
- Trial name
- NCT05443659
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 1,629 people
- Sponsor
- Theranica
Acute Migraine
Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
This will be a Phase 1, multiple center, open label, single-dose study in otherwise healthy adolescent subjects with a history of acute migraine. Subjects will each receive one Zecuity patch application.
- Trial name
- NCT02684409
- Testing
- PROT-CL-NP101-015.01
- Volunteers
- 37 people
- Sponsor
- NuPathe Inc.
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Acute Migraine
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine.
- Trial name
- NCT04089761
- Testing
- Nerivio
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theranica
Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine.
- Trial name
- NCT06995729
- Testing
- Zavegepant
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine Disorders
Migraine Study in Adolescent Patients
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
- Trial name
- NCT00843024
- Testing
- Sumatriptan and Naproxen Sodium
- Where
- 79 sites in United States
- Volunteers
- 589 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline